


This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. (Currently Amended) A method of decreasing intraocular pressure ~~or improving ocular accommodation~~ in an animal in need thereof, including a human, comprising administering
[[**(A)**]] an effective amount of ~~a cholinergic agent~~ pilocarpine; and
[[**(B)**]] an effective amount of a compound of the formula I:

(I)



wherein

[[**a.**]] R¹ and R² are

[[**1.**]] independently selected from hydrogen, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C₁-C₃)alkylenedioxy, allyl, amino, ω-alkylenesulfonic acid, carbamoyl, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, hydroxy, (C₂-C₆)hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, alkylsulfonyl, alkylsulfinyl, alkylthio, trifluoromethyl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, 4-[C₆ or C₁₀]arylpiperidin-1-yl, 4-[C₆ or C₁₀]arylpiperazin-1-yl, Ar, wherein, consistent with the rules of aromaticity, Ar is C₆ or C₁₀ aryl or a 5- or 6-membered heteroaryl ring, wherein 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring can be fused to a benzene, pyridine, pyrimidine, pyridazine, pyrazine, or (1,2,3)triazine, wherein the ring fusion is at a carbon-carbon double bond of Ar, Ar-alkyl, Ar-O, ArSO₂-, ArSO-, ArS-, ArSO₂NH-, ArNH, (N-Ar)(N-alkyl)N-, ArC(O)-, ArC(O)NH-, ArNH-C(O)-, and (N-Ar)(N-alkyl)N-C(O)-, or together R¹ and R² comprise methylenedioxy; ~~or~~
~~2. together with their ring carbons form a C₆-or C₁₀-aromatic fused ring system; or~~
~~3. together with their ring carbons form a C₅-C₇-fused cycloalkyl ring having up to two double bonds including any fused double bond of the olum or onium-containing ring, which~~

cycloalkyl ring can be substituted by one or more of the group consisting of alkyl, alkoxy, carbonyl, amino, aminocarbonyl, carboxy, fluoro, or oxo substituents; or

4. together with their ring carbons form a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring may be optionally substituted with one or more 1-pyrrolidinyl, 4-[C₆- or C₁₀]aryl, piperazin-1-yl, 4-[C₆- or C₁₀]aryl, piperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C₁-C₃)alkylenedioxy groups; or

5. together with their ring carbons form a five to eight membered heterocycle, wherein the heterocycle consists of ring atoms selected from the group consisting of carbon, nitrogen, and S(O)_n, where n=0,1, or 2;

[[b.]] Z is

- [[1.]] hydrogen, alkyl, Ar-CH₂;
2. a group of the formula -NR³R⁴, wherein R³ and R⁴ may be independently hydrogen, alkyl, Ar, or Ar-alkyl;
3. a group of the formula -CH(OR¹¹)R¹², wherein R¹¹ is hydrogen, methyl, ethyl or CH₂C(O)-; and R¹² is [C₁-to-C₆]alkyl, Ar, or CO₂R¹³ wherein R¹³ is hydrogen, methyl or ethyl;
4. a group of the formula -C(CO₂R¹³)(OR¹¹)R¹²;
5. a group of the formula -CH₂WAr, wherein W is (C=O) or S(O)_n where n=1 or 2; or
6. a group of the formula -CH₂C≡C-R¹⁴, wherein R¹⁴ is (C₁-C₆)alkyl;

[[c.]] Y is

1. amino, or

[[2.]] a group of the formula -CH(R⁵)-R⁶ wherein

[[a.]] R⁵ is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aminoalkyl, dialkylaminoalkyl, (N-[C₆- or C₁₀]aryl)(N-alkyl)aminoalkyl, piperidin-1-ylalkyl, 1-pyrrolidinylalkyl, azetidinylalkyl, 4-alkylpiperazin-1-ylalkyl, 4-alkylpiperidin-1-ylalkyl, 4-[C₆- or C₁₀]aryl, piperazin-1-ylalkyl, 4-[C₆- or C₁₀]aryl, piperidin-1-ylalkyl, azetidin-1-ylalkyl, morpholin-4-ylalkyl, thiomorpholin-4-ylalkyl, piperidin-1-ylalkyl, [C₆- or C₁₀]aryl, or independently the same as R⁶;

[[b.]] R⁶ is

(1) hydrogen, alkyl, which can be substituted by alkoxy, carbonyl, alkenyl, alkynyl, cyano or Rs, wherein Rs is a C₆- or C₁₀-aryl or a heterocycle containing 4-10 ring atoms

of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or

[(2)] a group of the formula $-W-R^7$, wherein R^7 is alkyl, alkoxy, hydroxy or Rs , wherein W is $-C(=O)-$ or $-S(O)_n-$ where $n=1$ or 2 and Rs is a C_6 aryl;

(3) a group of the formula $-W-OR^8$ wherein R^8 is hydrogen or alkyl;

(4) a group of the formula $-CH(OH)Rs$; or

(5) a group of the formula $-W-N(R^9)R^{10}$, wherein

[a] R^9 is hydrogen and R^{10} is an alkyl or cycloalkyl, optionally substituted by

(i) $[C_6\text{ or }C_{10}]$ aryl, or

(ii) a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, said heteroaryl ring can be optionally substituted with one or more 1-pyrrolidinyl, 4- $[C_6\text{ or }C_{10}]$ arylpiperazin-1-yl, 4- $[C_6\text{ or }C_{10}]$ arylpiperidin-1-yl, azetidin-1-yl, and morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C_1-C_3) alkylenedioxy groups, or fused to a substituted phenyl or pyridine ring, wherein the ring fusion is at a carbon-carbon double bond of the heteroaryl ring, or

(iii) a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or

[b] R^9 is hydrogen or lower alkyl and R^{10} is Ar; or

[c] R^9 is hydrogen or lower alkyl, and R^{10} is a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, said heterocycle; or

[d] R^9 and R^{10} are both alkyl groups; or

[e] R^9 and R^{10} together with N form a heterocycle containing 4-10 ring atoms which can incorporate up to one additional heteroatom selected from the group of N, O or S in the ring, wherein the heterocycle is optionally substituted with $(C_6\text{ or }C_{10})$ aryl, $(C_6\text{ or }C_{10})$ arylalkyl, or a 5- or 6-membered heteroaryl ring, wherein the 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each such heteroaryl can be optionally substituted with one

~~or more 1-pyrrolidinyl, 4-[C₆ or C₁₀]aryl piperazin-1-yl, 4-[C₆ or C₁₀]aryl piperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, halo or (C₁-C₃)alkylenedioxy; or~~
~~{f} R⁹ and R¹⁰ are both hydrogen; or~~

[[d.]] Q is N, O or S;

[[e.]] M is absent when Q is O or S;

~~f. M is alkyl, vinyl or allyl, or independently the same as Y; and~~

[[g.]] X is a pharmaceutically acceptable anion, or

[[C.]] a pharmaceutically acceptable salt of the compound, and

wherein aryl or Ar can be substituted with, in addition to any substitutions specifically noted, one or more substituents selected from the group consisting of acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C₁-C₃)alkylenedioxy, alkylsulfonyl, alkylsulfinyl, ω-alkylenesulfonic acid, alkylthio, allyl, amino, ArC(O)-, ArC(O)NH-, ArO-, Ar-, Ar-alkyl-, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, trifluoromethyl, hydroxy, (C₂-C₆)hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, 1-pyrrolidinyl, 4-[C₆ or C₁₀]aryl piperazin-1-yl-, 4-[C₆ or C₁₀]aryl piperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl; and

~~wherein heterocycles, except those of Ar, can be substituted with, in addition to any substitutions specifically noted, acylamino, alkanoyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, alkylsulfonyl, alkylsulfinyl, alkylthio, amino, ArC(O)-, ArO-, Ar-, carboxy, dialkylamino, fluoro, fluoroalkyl, difluoroalkyl, hydroxy, mercapto, sulfamoyl, or trifluoromethyl.~~

2-12. (Cancelled).

13. (Previously Presented) The method of claim 1, wherein the compound of the formula I is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

14.-15. (Canceled)

16. (Previously Presented) The method of claim 1, wherein said compounds are administered intravenously.
17. (Previously Presented) The method of claim 1, wherein said compounds are administered intracamerally.
18. (New) The method of claim 1, wherein R_1 is alkyl.
19. (New) The method of claim 1, wherein R_2 is alkyl.
20. (New) The method of claim 1, wherein R_1 and R_2 are both alkyl.
21. (New) The method of claim 1, wherein R_1 is methyl.
22. (New) The method of claim 1, wherein R_2 is methyl.
23. (New) The method of claim 1, wherein R_s is unsubstituted phenyl.
24. (New) The method of claim 1, wherein X is halogen.
25. (New) The method of claim 1, wherein X is chloride or bromide.
26. (New) The method of claim 1, wherein the compound of formula I is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide
27. (New) The method of claim 1, wherein the decreased intraocular pressure treats glaucoma.
28. (New) A method of decreasing intraocular pressure in an animal in need thereof, including a human, comprising administering an effective amount of pilocarpine and 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

29. (New) The method of claim 28, wherein the decreased intraocular pressure treats glaucoma.